Meeting
2024 ASCO Annual Meeting
Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.
Presenter
Ari Joseph Rosenberg, MD
University of Chicago, Department of Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Rapid Oral Abstract Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT05108870
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 6017)
DOI
10.1200/JCO.2024.42.16_suppl.6017
Abstract #
6017
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.
Speaker: Ari Rosenberg, MD
Videos & Slides
2021 ASCO Annual Meeting
Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC.
Speaker: Marshall R. Posner, MD
Speaker: Panel Discussion
Speaker: Panel Discussion